So at the start of this module, I mentioned the history of bronchiectasis, a disease, a Cinderella disease, the most neglected disease in respiratory medicine, uh, and so it's really nice to think what's happened in the last 10 to 15 years, um, that bronchiectis has now entered a new era, we have the first licensed therapy for the disease, it's something that targets, The central pillar of the pathophysiology, which is neutrophilic inflammation, and a medicine that was developed specifically for, uh, bronch patients with bronchiectasis, it opens up an entirely new avenue of treatment, you know, we have the potential now to think about disease modification, preventative therapy, proactive management of our patients. And recognizing bronchiectis as an inflammatory disease opens up other future treatments as well, and bronchiectis is now a very exciting, uh, space in terms of the evolving science, uh, and we're seeing also development of new clinical services, uh, and more information, more, um, support for patients. So it's a really exciting time to be involved in bronchiectis, it shows to me the power of translational science to take. A, a neglected condition with no standard of care to now to this point where we really do have, uh, evolving options, exciting new science, um, and the first licensed therapy. So this is a, uh, bronchiexis is now a success story, and hopefully some of the information that we've shared in this module, uh, can help you with the management of your patients and, uh, and in growing the, the interest and the support for people with bronchiectis.
Presenter
